Carotuximab（Cat No.:I042144）is an investigational monoclonal antibody that targets the protein EGFR (epidermal growth factor receptor), which is often overexpressed in various cancers, including head and neck cancer, non-small cell lung cancer, and colorectal cancer. By binding to EGFR, carotuximab inhibits cancer cell growth, signaling, and survival, while also promoting immune system responses against tumors. It is being studied in clinical trials as a potential treatment for EGFR-positive cancers, with the aim of improving patient outcomes by disrupting cancer progression and enhancing the efficacy of other therapies when used in combination.
